Basal cell nevus syndrome Q82.8

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 13.10.2026

Dieser Artikel auf Deutsch

Synonym(s)

Basal cell carcinoma syndrome naevoides; Basal cell nevus syndrome; basocellular carcinoma naevoides; BCNS; BZNS; Hereditary cutaneo-mandibular polyoncosis; Hermans-Grosfeld-Spaas-Valk disease; Naevo basal cell carcinomas; Naevo-basal cell carcinomatosis; Nevoid basal cell carcinomas; Nevoid basal cell carcinoma syndrome; OMIM 109400; Polyoncosis hereditary cutaneo-mandibular; Ward syndrome

History
This section has been translated automatically.

Kaposi, 1872; Robert W. Goltz and Robert J.Gorlin, 1960.

Note: Although Gorlin described many syndromes, several of which received his name, none is so closely associated with his name as the nevoid basal cell carcinoma syndrome.

Definition
This section has been translated automatically.

Nevoid basal cell carcinoma syndrome, also known as Gorlin-Goltz syndrome, is an autosomaldominant multisystem disorder characterized by the occurrence of numerous basal cell carcinomas at an early age, as well as multiple other malformations, particularly of the skeletal system, the central nervous system, the urogenital system, and the heart. 

The main symptoms are:

  • (prematurely developing) basal cell carcinomas
  • jaw cysts
  • Pits
  • Calcifications of the falx cerebri and
  • medulloblastomas.   

Occurrence/Epidemiology
This section has been translated automatically.

Prevalence (Europe) about 1/57,000 - 1:256,000 patients. It is lower in East Asia, where it is between 1:235,800 and 1:13,939,393.

In up to 40% of cases, the family history is negative, so that a correspondingly high rate of new mutations can be assumed.

Etiopathogenesis
This section has been translated automatically.

Autosomal dominant inheritance with incomplete penetrance of mutations of the gene loci 9q22.3(PTCH1 tumor suppressor gene), 9q31 and 1p32 (see below Hedgehog signaling pathway).

The autosomal dominant inherited nevoid basal cell carcinoma syndrome (BCNS) can be caused by mutations in 3 different genes:

  • PTCH1 gene (PTCH = tumor suppressor gene, 601309) on chromosome 9q22
  • PTCH2 gene (603673) on chromosome 1p32
  • SUFU gene (607035) on chromosome 10q24-q25.

Somatic mutations in the PTCH2 gene have also been identified in solitary basal cell carcinoma (605462) and medulloblastoma (155255). Both malignancies are characteristics of the nevoid basal cell carcinoma syndrome.

More than 70 germline mutations have now been found in patients with Gorlin-Goltz syndrome. The PTCH gene encodes a transmembrane protein (PTCH) that acts as a receptor in the Sonic-Hedgehog signaling cascade. This activation usually occurs through the binding of SHH to PTCH. This removes the inhibitory effect of PTCH on the cell membrane protein Smoothened (SMO). This allows signals to be transmitted into the intercellular space up to the cell nucleus. In the cell nucleus, further activation of transcription factors (e.g. Gli1 = glioma-associated onogenic homolog) occurs, which in turn induce genes in the cell nucleus that lead to cell cycle progression and cell proliferation (Hübner L 2014).

Linear basal cell carcinomas: Basal cell carcinomas in a linear arrangement are regarded as a special form of nevoid basal cell carcinoma syndrome (Gorlin-Goltz syndrome).

Manifestation
This section has been translated automatically.

Can occur at any age. Mostly occurring in early adulthood.

Clinic
This section has been translated automatically.

Skin: Multiple, closely spaced basal cell carcinomas (mostly of the nodulo-ulcerative type, some of which are pigmented), primarily on the face, but also on the trunk and extremities. The first basal cell carcinomas can appear even before the age of 20. Slow growth; the tumor size may remain stable for years. Some individual tumors may experience sudden, expansive growth accompanied by ulcerations and tissue destruction. In nearly 90% of cases, pitted palmoplantar keratoses (pits) are present. In addition, lipomas, epidermal cysts, and milia are present on the skin.

Skeletal system: odontogenic jaw cysts, rib cysts, dental malformations, forked ribs, spina bifida, scoliosis, frontal bossing, broadened nasal bridge, shortened metacarpal bones (4th and 5th metacarpals), syndactyly.

CNS: macrocephaly, agenesis of the corpus callosum (10% of cases), calcifications of the falx cerebri, cataracts, congenital amaurosis, and occasionally mental retardation; 5% of affected individuals develop a cerebellar medulloblastoma as early as childhood.

Genital tract: Optional calcifications of the ovary, ovarian fibromas. In male patients, optional hypogonadism.

Case reports compiled from the literature:

  • Gorlin and Goltz (1960) described a familial syndrome characterized by multiple nevoid basal cell epitheliomas, jaw cysts, and bifid ribs. The inheritance pattern was autosomal dominant.
  • Herzberg and Wiskemann (1963) described what they termed the “fifth phakomatosis,” a basal cell nevus syndrome with medulloblastoma. They reported on a family in which both the father and the son had basal cell carcinomas, with the son additionally having a medulloblastoma and congenital thoracic scoliosis.
  • Cawson and Kerr (1964) described a syndrome characterized by jaw cysts, basal cell carcinomas, and skeletal anomalies. One of the patients also had an astrocytoma with severe hydrocephalus. Additional features included pits on the palms and soles.
  • Lile et al. (1968) observed 4 cases across 3 generations of a family. Two of the patients had a short terminal phalanx of the thumb.
  • Berlin et al. (1966) observed an ovarian carcinoma associated with this syndrome.
  • Holubar et al. (1970) found basal cell epitheliomas in multiple palmar pits in an 8-year-old girl with BCNS.
  • Schwartz (1978) identified hamartomatous polyps of the stomach and mesenteric cysts as features of basal cell nevus syndrome. Totten (1980) observed a large congenital pulmonary cyst occupying the left thoracic cavity in an affected patient.
  • Cramer and Niederdellmann (1983) described 9 individuals from 3 families with cerebral gigantism syndrome (117550); 7 of the patients also had signs of nevoid basal cell carcinoma syndrome. In one family, the elderly father and son had jaw cysts and other signs of nevoid basal cell carcinoma syndrome. A second son suffered from macrocephaly, mild hydrocephalus, intracranial calcifications, and EEG abnormalities.
  • Koch et al. (2002) described a 13-year-old boy with NBCCS and a mesenchymal liver tumor. At the age of 3, he had been treated for a medulloblastoma with resection and radiation therapy.

Diagnosis
This section has been translated automatically.

  • Diagnosis of clinical complications according to Evans:
    • Major criteria:
      • More than 2 basal cell carcinomas or 1 basal cell carcinoma before LJ 30
      • Jaw cysts before the 20th LJ
      • Palmare or plantar dimples (> 3)
      • Calcification of the falx cerebri
      • Medulloblastoma, especially desmoplastic type
      • Positive family history (1st degree relatives with BZNS)
    • Secondary criteria:
      • Congenital skeletal anomalies:
        • Split, fused or missing ribs
        • Split or fused vertebral bodies
      • Frontooccipital head circumference (> 97th percentile, with frontal bumps)
      • Cardiac or ovarian fibroids
      • Congenital malformation: cleft lip, jaw, palate, polydactyly, cataract, iriscoloboma.

Notice! A diagnosis is made when 2 major criteria or 1 major criterion and 2 minor criteria are met.

Therapy
This section has been translated automatically.

The therapeutic goal in multiple basal cell carcinoma is to maintain the quality of life. The goal of basal cell carcinoma is to achieve freedom from tumours and excision in healthy people, but this is not always possible. Curettage and cryosurgery, especially in old age, even if the absence of tumours in loco is not guaranteed in these procedures.

External therapy
This section has been translated automatically.

Good success with 5% Imiquimod cream (Aldara; off-label use!) for 6-8 weeks in some cases.

Internal therapy
This section has been translated automatically.

Prophylaxis with acitretin (neotigason) 0.5 mg/kg bw/day p.o.

New studies show good results with pembrolizumab.

Literature
This section has been translated automatically.

  1. Anderson DE et al (1967) The nevoid basal cell carcinoma syndrome. Am J Hum Genet 19: 12-22
  2. Bale AE (1997) Variable expressivity of patched mutations in flies and humans. (Editorial) Am. J Hum Gene 60: 10-12.
  3. Berlin NI et al (1966) Basal cell nevus syndrome. Ann.Intern Med 64: 403-421.
  4. Boutet N et al (2003) Spectrum of PTCH1 mutations in French patients with Gorlin syndrome. J Invest Dermatol 121: 478-481.
  5. Burgdorf WHC et al (1988) Autosomal dominant genodermatoses and their association with internal carcinomas. Dermatol 39: 413-418
  6. Cawson R A et al (1964) The syndrome of jaw cysts, basal cell tumours and skeletal anomalies. Proc Roy Soc Med 57: 799-801
  7. Cramer H et al (1983) Cerebral gigantism associated with jaw cyst basal cell naevoid syndrome in two families. Arch Psychiat Nervenkr 233: 111-124.
  8. Evans DGR et al (1993) Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 30: 460-464
  9. Fink-Puches R et al (1994) Retinoids in the chemoprevention of skin and mucosal tumors. Dermatologist 45: 671-677
  10. Gorlin RJ, Goltz RW (1960) Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 262: 908-912
  11. Happle R (2000) Nonsyndromic type of hereditary multiple basal cell carcinoma. Am J Med Genet 95: 161-163
  12. Herzberg J J et al (1963) The fifth phakomatosis. Basal cell nevus with familial burden and medulloblastoma. Dermatologica 126: 106-123
  13. Holubar K et al (1970) Multiple palmar basal cell epitheliomas in basal cell nevus syndrome. Arch Derm 101: 679-682.
  14. Hübinger L et al (2014) Genodermatoses associated with malignant skin tumors. Dermatologist 65: 527-535
  15. Kaposi M (1872) Idiopathic multiple pigmentary sarcoma of the skin. Archives of dermatology and syphilis (Prague) 4: 265-273.
  16. Koch CA et al (2002) Two-hit model for tumorigenesis of nevoid basal cell carcinoma (Gorlin) syndrome-associated hepatic mesenchymal tumor. (Letter) Am J Med Genet 109: 74-76.
  17. LeSueur BW et al (2003) Axillary basal cell carcinoma. Dermatol Surg 29: 1105-1108.
  18. Lile HA et a. (1999) The basal cell nevus syndrome. Am J Roentgen Radium Ther. Nucl Med 103: 214-217.
  19. Linß G, Burhardt E, Reis A (2000) Correlation between patched gene mutation and clinical presentation in basal cell nevus syndrome (Gorlin syndrome). In: Plettenberg A, Meigel WN, Moll I (eds) Dermatology on the threshold of the new millennium. Springer, Berlin Heidelberg New York, pp. 559-561.
  20. Mirowski GW (2002) Nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 43: 1092-1093
  21. Reifenberger J (2004) Hereditary tumor syndromes. Dermatologist 55: 942-951
  22. Schwartz,RA (1994) Basal-cell nevus syndrome and gastrointestinal polyposis. (Letter) New Eng J Med 299: 49
  23. Schulz-Butulis BA et al (2000) Nevoid basal cell carcinoma syndrome and non-Hodgkin's lymphoma. Cutis 66: 35-38
  24. Stockfleth E (2002) Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 12: 569-572

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 13.10.2026